Search results for " Pharmaceutical Preparations"

showing 5 items of 5 documents

Are there positive lessons for Italy's NHS resulting from the Covid-19 pandemic?

2020

The authors evaluate the importance of prevention measures and health care from their own experience and briefly analyse the factors that may have contributed to the rapid spread of Covid-19 in Italy, and hope this will feed into appropriate and new and improved health policies.

2019-20 coronavirus outbreakNational Health ProgramsCoronavirus disease 2019 (COVID-19)Pneumonia ViralMEDLINEStrategic StockpileBetacoronavirusSettore MED/43 - Medicina LegalePolitical scienceEnvironmental healthPandemicHealth careHumansPandemicsPersonal Protective EquipmentStrategic StockpileHealth policyHealth Services Needs and DemandbiologySARS-CoV-2business.industryHealth PolicyCOVID-19General Medicinebiology.organism_classificationItalyPharmaceutical PreparationsCommunicable Disease Controlcoronavirus pandemic Covid-19 health care health policies lessons Coronavirus Infections Health Services Needs and Demand Humans Italy Pandemics Personal Protective Equipment Pharmaceutical Preparations Pneumonia Viral Strategic Stockpile Betacoronavirus Communicable Disease Control Health Policy National Health ProgramsCoronavirus InfectionsbusinessBetacoronavirus
researchProduct

Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

2020

Abstract Background In 2016, an expert working group was convened under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and formulated consensus recommendations for the conduct of clinical trials for drugs to prevent or treat sarcopenia. Aims The objective of the current paper is to provide a 2020 update of the previous recommendations in accordance with the evidence that has become available since our original recommendations. Methods This paper is based on literature reviews performed by members of the ESCEO working group and followed up with face to face meetings organized for the whole group to make amendments and discuss…

AgingSarcopeniaGeriatrics & GerontologyStandardizationDiseaseReviewRecommendationsFace-to-face0302 clinical medicineQUALITY-OF-LIFEGAIT SPEEDClinical trial; Drug registration; Guidelines; Recommendations; Sarcopenia; Treatment; Aged; Humans; Muscle Strength; Osteoarthritis; Osteoporosis; Pharmaceutical Preparations; Sarcopenia030212 general & internal medicineMUSCLE MASSDIETARY-PROTEINClinical trialPhysical limitationsPharmaceutical Preparations/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPatient-reported outcomeGRIP STRENGTHLife Sciences & Biomedicinemedicine.medical_specialtyNUTRITIONAL-STATUSBODY-COMPOSITION030209 endocrinology & metabolismGuidelines03 medical and health sciencesClinical trial · Sarcopenia · Guidelines · Recommendations · Drug registration · TreatmentSDG 3 - Good Health and Well-beingOsteoarthritismedicineHumansMuscle StrengthDrug registrationAgedScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseComorbidityClinical trialTreatmentSarcopeniaPATIENT-REPORTED OUTCOMESPhysical therapyOsteoporosisGeriatrics and GerontologyPHYSICAL PERFORMANCEbusinessAging Clinical and Experimental Research
researchProduct

Different effects of biological drugs in rheumatoid arthritis

2013

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity. Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) t…

Cartilage Articularmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsImmunologyArthritisPharmacologyArthritis Rheumatoidchemistry.chemical_compoundChondrocytesPharmacotherapyTocilizumabDrug TherapyRheumatoidInternal medicinemedicineHumansImmunology and AllergyArthritis Rheumatoid; Cartilage Articular; Chondrocytes; Drug Therapy Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation Mediators; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alphaAdverse effectRandomized Controlled Trials as TopicTumor Necrosis Factor-alphabusiness.industryArthritisAbataceptmedicine.diseaseClinical trialCartilagePharmaceutical PreparationschemistryRheumatoid arthritisCombinationDrug Therapy CombinationRituximabInflammation MediatorsbusinessArticularmedicine.drugAutoimmunity Reviews
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Does anti-inflammatory drugs modify the severe odontogenic infection prognosis? A 10-year’s experience

2020

Background Numerous biochemical datas support the noxious role of anti-inflammatory drugs on immune response. Those observations are often put forward for unfavorable evolution of odontogenic infection but has never been really proven in clinic. The aim of this study is to try to clarify this role based on the collection of the clinical course of odontogenic infections over a 10-year analysis period. Material and Methods The investigators implemented a prospective observational study. The sample was composed of patients managed between January 2004 and December 2014 for severe odontogenic infection based on three criteria: hospital admission, intravenous antibiotic therapy, tooth extraction…

medicine.medical_specialtytumorErythemamedicine.drug_classMESH: Pharmaceutical PreparationsPopulationAnti-Inflammatory AgentsPaincarcinomaMESH: Prognosislip03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASOdontogenic infectioncystUnivariate analysiseducation.field_of_studyMESH: Humansbusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistrymedicine.diseasePrognosisMESH: Anti-Inflammatory Agents Non-SteroidalOtorhinolaryngologyPharmaceutical PreparationsMESH: Anti-Inflammatory AgentsPropensity score matching[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCorticosteroidSurgeryObservational studyMESH: Painmedicine.symptomOral SurgerybusinessOdynophagianeoplasm
researchProduct